On the basis of elevated [18F]-AV1451 binding in the medial temporal lobe, tau imaging could also be used to improve the identification and enrollment of probable patients with DLB into clinical trials to assess the therapeutic potential of antitau interventions. Here, MAPT is linked to Lewy body dementia.